New product: Lagevrio (molnupiravir) 200 mg hard capsules
This ribonucleoside analog β-D-N4-hydroxycytidine broad spectrum antiviral is licensed for treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 test and at least one risk factor for developing severe illness at a dose of 800mg twice daily for 5 days.
Source:
electronic Medicines compendium
SPS commentary:
The MHRA approved this treatment on November 4th. The government will be confirming how this COVID-19 treatment will be deployed to patients in due course.